OptiMAL will be presented in December at a key US conference following grant of a key US patent protecting the platform till 2042. A licensing/franchise strategy could enable faster revenue generation. The NIH collaboration should provide solid proof of concept. By gaining significant Northern Ireland grants (worth £1.55m in total), Fusion Antibodies will accelerate its development to drive long term growth and save £300k of costs. The financial 2025 results (year to 31 March) showed a 73% rise ....